Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Oct 23;1878(1):131. doi: 10.1007/s40278-021-04101-8

Bumetanide

Metabolic alkalosis: case report

PMCID: PMC8532425

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A 67-year-old man developed metabolic alkalosis during treatment with bumetanide for diuretic therapy1 .

The man, who had hypertension and diabetes, presented with hypoxia due to COVID-19 pneumonia. He was hospitalised and intubated for hypercapnic respiratory failure. Because of worsening dyspnoea, he was started on bumetanide drip [dosage and route not stated] on day 34 of admission; however, due to diuresis with bumetanide, bicarbonate concentration (HCO3-), partial pressure of carbon dioxide (paCO2) and arterial pH increased. On day 46 bicarbonate concentration reached 70 mEq/L, causing severe metabolic alkalosis.

The man's bumetanide treatment was stopped. His condition improved. Subsequently, he developed acute kidney injury, oliguria and azotaemia with a rise in serum creatinine. He had worsening anion gap metabolic acidosis secondary to uraemia. His COVID-19 worsened leading to acute tubular necrosis and worsening septic shock. Owing to his multi-organ failure, he was transferred to comfort care on day 51. He died after few hours due to multi-organ failure.

Footnotes

1

Country of occurrence, reporter country and primary source country not stated. Unable to contact author.

Reference

  1. Chen Etchison E, et al. SEVERE RESPIRATORY ACIDOSIS AND METABOLIC ALKALOSIS IN A PATIENT WITH COVID-19 ARDS. Chest 160 (Suppl.): A2154, No. 4, 1 Oct 2021. Available from: URL: 10.1016/j.chest.2021.07.1903 [abstract] [DOI]

Articles from Reactions Weekly are provided here courtesy of Nature Publishing Group

RESOURCES